AU2002329061A1 - Gene and protein relating to hepatocellular carcinoma - Google Patents

Gene and protein relating to hepatocellular carcinoma

Info

Publication number
AU2002329061A1
AU2002329061A1 AU2002329061A AU2002329061A AU2002329061A1 AU 2002329061 A1 AU2002329061 A1 AU 2002329061A1 AU 2002329061 A AU2002329061 A AU 2002329061A AU 2002329061 A AU2002329061 A AU 2002329061A AU 2002329061 A1 AU2002329061 A1 AU 2002329061A1
Authority
AU
Australia
Prior art keywords
gene
hepatocellular carcinoma
protein relating
protein
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002329061A
Other languages
English (en)
Inventor
Yoichi Furukawa
Yusuke Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
University of Tokyo NUC
Original Assignee
Oncotherapy Science Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2399569 external-priority patent/CA2399569A1/en
Application filed by Oncotherapy Science Inc, University of Tokyo NUC filed Critical Oncotherapy Science Inc
Publication of AU2002329061A1 publication Critical patent/AU2002329061A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809Methods for determination or identification of nucleic acids involving differential detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2002329061A 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma Abandoned AU2002329061A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32426101P 2001-09-25 2001-09-25
US60/324,261 2001-09-25
US39166602P 2002-06-26 2002-06-26
US60/391,666 2002-06-26
CA 2399569 CA2399569A1 (en) 2001-09-25 2002-08-23 Diagnostic markers and drug targets for treatment of cancer
CA2,399,569 2002-08-23
PCT/JP2002/009876 WO2003027143A2 (en) 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
AU2002329061A1 true AU2002329061A1 (en) 2003-04-07

Family

ID=27171637

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002329061A Abandoned AU2002329061A1 (en) 2001-09-25 2002-09-25 Gene and protein relating to hepatocellular carcinoma

Country Status (9)

Country Link
US (3) US7767392B2 (enExample)
EP (1) EP1430152B1 (enExample)
JP (1) JP4353798B2 (enExample)
CN (1) CN1628179B (enExample)
AT (1) ATE356223T1 (enExample)
AU (1) AU2002329061A1 (enExample)
DE (1) DE60218710T2 (enExample)
ES (1) ES2283592T3 (enExample)
WO (1) WO2003027143A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
ES2283592T3 (es) 2001-09-25 2007-11-01 Oncotherapy Science, Inc. Gen y proteina relacionados con el carcinoma hepatocelular.
DE602004032114D1 (de) * 2003-02-28 2011-05-19 Oncotherapy Science Inc Rna-interferenz für das gen znfn3a1 als verfahren zur hemmung des wachstums von krebszellen
JP2007506425A (ja) * 2003-09-24 2007-03-22 オンコセラピー・サイエンス株式会社 肝細胞癌を診断する方法
TWI350373B (en) * 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US20060189560A1 (en) * 2005-01-27 2006-08-24 Ajit Kumar Molecular method to augment RNA mediated gene silencing
US7939254B2 (en) * 2005-02-28 2011-05-10 Oncotherapy Science, Inc. Breast cancer related gene ZNFN3A1
WO2006121208A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Polymorphisms of the e2f-1 binding element and methods of determining cancer susceptibility
TW200741009A (en) * 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
US8354223B2 (en) 2007-06-14 2013-01-15 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3
EP2405269B8 (en) 2009-03-05 2016-10-12 National Institute of Advanced Industrial Science And Technology Method for detecting and distinguishing intrahepatic cholangiocarcinoma
US20110021362A1 (en) * 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US20140308678A1 (en) 2011-12-02 2014-10-16 Oncotherapy Science, Inc. Smyd2 as a target gene for cancer therapy and diagnosis
WO2014141652A1 (en) * 2013-03-11 2014-09-18 Oncotherapy Science, Inc. Smyd3 peptides and vaccines containing the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999039200A1 (en) 1998-01-29 1999-08-05 Thomas Jefferson University Molecular markers for diagnosing hepatocellular carcinoma
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000017355A2 (en) 1998-09-18 2000-03-30 Incyte Pharmaceuticals, Inc. Human cytoskeleton associated proteins
AU2743400A (en) * 1999-01-29 2000-08-18 Incyte Pharmaceuticals, Inc. Nucleic-acid binding proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2001029221A2 (en) 1999-10-20 2001-04-26 Zymogenetics, Inc. Proteins and polynucleotides encoding them
AU783762B2 (en) 1999-12-23 2005-12-01 Arca Biopharma, Inc. Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
EP1591448A3 (en) 2000-04-18 2006-01-11 Nuvelo, Inc. Novel nucleic acids and polypeptides
MXPA03006617A (es) 2001-01-24 2004-12-02 Protein Design Labs Inc Metodos de diagnostico de cancer de pecho, composiciones y metodos de rastreo de moduladores de cancer de pecho.
GB0111218D0 (en) 2001-05-08 2001-06-27 Cancer Res Ventures Ltd Assays methods and means
WO2002092002A2 (en) 2001-05-11 2002-11-21 The Burnham Institute Screening, diagnostic and therapeutic methods relating to riz
CA2454183C (en) 2001-07-23 2016-09-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
ES2283592T3 (es) * 2001-09-25 2007-11-01 Oncotherapy Science, Inc. Gen y proteina relacionados con el carcinoma hepatocelular.
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
EP1453532A4 (en) * 2001-12-13 2007-03-28 Exelixis Inc TAOJIKS AS MODIFICATORS OF THE BETA-CATENIN PATH AND METHOD OF USE
DE602004032114D1 (de) 2003-02-28 2011-05-19 Oncotherapy Science Inc Rna-interferenz für das gen znfn3a1 als verfahren zur hemmung des wachstums von krebszellen
TWI350373B (en) * 2004-01-23 2011-10-11 Oncotherapy Science Inc Methods of detecting methyl transferase activity and methods of screening formethyl transferase activity modulators
US7939254B2 (en) * 2005-02-28 2011-05-10 Oncotherapy Science, Inc. Breast cancer related gene ZNFN3A1
TW200741009A (en) * 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer
US8354223B2 (en) 2007-06-14 2013-01-15 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3

Also Published As

Publication number Publication date
DE60218710T2 (de) 2007-12-06
ATE356223T1 (de) 2007-03-15
CN1628179A (zh) 2005-06-15
WO2003027143A2 (en) 2003-04-03
EP1430152B1 (en) 2007-03-07
US20100248240A1 (en) 2010-09-30
DE60218710D1 (de) 2007-04-19
JP2005511023A (ja) 2005-04-28
JP4353798B2 (ja) 2009-10-28
ES2283592T3 (es) 2007-11-01
US8148080B2 (en) 2012-04-03
EP1430152A2 (en) 2004-06-23
WO2003027143A3 (en) 2003-10-30
CN1628179B (zh) 2011-04-20
US7767392B2 (en) 2010-08-03
US20120149762A1 (en) 2012-06-14
US20040235018A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
AU2002329061A1 (en) Gene and protein relating to hepatocellular carcinoma
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
WO2004043361A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
WO2001064922A3 (en) Heterologous expression of neisserial proteins
LTPA2015049I1 (lt) Žpv 45 l1 optimizuota ekspresija mielėse
WO2004024068A3 (en) Novel composition and methods for the treatment of immune related diseases
ZA200405388B (en) Binding proteins as biosensors
WO2002072845A3 (en) Salmonella promoter for heterologous gene expression
WO2005028630A3 (en) Engineered zinc finger proteins for regulation of gene expression
WO2004112829A3 (en) Compositions and methods for the diagnosis and treatment of tumors of glial origin
AU2003270626A1 (en) Magnetically modified electrodes as well as methods of making and using the same
WO2005049075A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
WO2004013307A3 (en) Compounds for targeting hepatocytes
AU2003240221A1 (en) Genes and polypeptides relating to hepatocellular or colorectal carcinoma
AU2002249787A1 (en) Compositions and methods relating to lung specific genes and proteins
AU2002219960A1 (en) Molecules of the card-related protein family and uses thereof
WO2004024064A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
AU2003262727A1 (en) Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents
AU2003243381A1 (en) Variants of antithrombin iii
AU1539801A (en) Transcription factors containing two potential dna binding motifs
WO2004006864A3 (en) Methods and compositions for the enhancement of wound healing

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase